Novavax (NVAX) Misses Q4 EPS by 1c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $3.95 -4.82%
EPS Growth %: +72.1%
Financial Fact:
Net loss: -66.25M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +72.1%
Financial Fact:
Net loss: -66.25M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Note: EPS may not be comparable
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.98 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
- Primis Financial (FRST) Misses Q1 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
